Syndax Pharmaceuticals Inc. (SNDX) stock plummeted 8.27% in Tuesday's pre-market session, indicating a lower open for the biopharmaceutical company's shares.

The pre-market plunge comes as Syndax disclosed new risks related to its revenue growth prospects. According to the company's disclosure, it faces challenges in navigating regulatory hurdles and market conditions that could impact its ability to drive revenue growth.

Investors appear to be reacting negatively to these disclosed risks, which introduce uncertainties around Syndax's future financial performance and growth trajectory. The stock's pre-market decline suggests market participants are pricing in these potential headwinds and their potential impact on the company's valuation.